Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Could Be Mostly Spared From Trump's Regulation-Slashing Order

Executive Summary

Even though the executive order that requires regulatory offsets may only have limited application to the agency, industry experts warn that it still could prove to be unwieldly to implement.

Advertisement

Related Content

Shuren At FDLI: Least-Burdensome, Real-World Evidence Efforts Picking Up
Public Citizen Challenges Trump's Regulation Executive Order
Trump Order Reducing Regulation Might Imperil FDA Good Guidance Practices
Trump's Two-For-One Reg Order Needs Agency Interpretation, Medtech Reg Experts Say
FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival

Topics

Advertisement
UsernamePublicRestriction

Register

MT104436

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel